Clarivate Epidemiology’s coverage of acute lymphoblastic leukemia (ALL) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of ALL for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.
Clarivate Epidemiology’s ALL forecast will answer the following questions:
- Of all people diagnosed with ALL, how many in each country in the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALL over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following ALL subpopulations:
- Second-line B-cell receptor-Abelson leukemia virus (BCR–ABL)-positive drug-treatable older adult population.
- Second-line BCR–ABL-negative drug-treatable older adult population.
- Second-line BCR–ABL-positive drug-treatable adolescent and young adult population.
- Second-line BCR–ABL-negative drug-treatable adolescent and young adult population.
- Second-line BCR–ABL-negative drug-treatable pediatric population.
- Second-line BCR–ABL-positive drug-treatable pediatric population.
- Third- and fourth-line BCR–ABL-positive drug-treatable adolescent and young adult population.
- Third- and fourth-line BCR–ABL-negative drug-treatable adolescent and young adult population.
- Third- and fourth-line BCR–ABL-positive drug-treatable older adult population.
- Third- and fourth-line BCR–ABL-negative drug-treatable older adult population.
- … and many more (details available on request).
Note: Coverage may vary by country.
- Acute Lymphoblastic Leukemia - Epidemiology - Emerging Markets
- Key Findings
- Incidence of Acute Lymphoblastic Leukemia per 100,000 People of All Ages per Year in 2021 and 2031ttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Lymphoblastic Leukemia Over the Next 10 Yearsttttttttt
- Number of Additional Incident Cases of Acute Lymphoblastic Leukemia Incurred Over 2021-2031 in the Countries Under Studyttttttttt
- Epidemiology Data
- Diagnosed Incident Cases
- Diagnosed Prevalent Cases
- Age Distribution
- BCR-ABL Status
- Precursor B-Cell Immunophenotype
- Drug-Treatable and Drug-Treated Populations
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Acute Lymphoblastic Leukemia
- Risk/Protective Factors
- Risk/Protective Factors for Acute Lymphoblastic Leukemia